Full Press Release Details
Adagene Presents Data Demonstrating First and Best-in-Class Potential
for Differentiated Preclinical Antibody
Candidates at American Association for Cancer
Research (AACR) Annual Meeting 2022
presentations showcase SAFEbody precision masking technology applicability across
targets and modalities -
- IND or equivalent filings planned for two
new product candidates in 2022, including masked anti-
CD137 antibody with Fc engineering and masked anti-CD47 antibody, designed
to enhance both safety and efficacy -
SAN DIEGO and SUZHOU, China,
April 8, 2022 - Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and
development of novel antibody-based therapies, today announced preclinical data showcasing the potential first/best-in-class
profile of new antibody candidates. Data are being presented at the American Association for Cancer Research (AACR) Annual Meeting,
taking place in New Orleans, Louisiana from April 8-13, 2022. Posters are available in the Publications section of the
company's website at www.adagene.com.
"We are encouraged by the preclinical data presented across
four posters at AACR, showing the first/best-in-class profiles for our differentiated preclinical candidates, designed to achieve
safe, potent and durable responses. These include ADG206, a masked, IgG1 Fc engineered anti-CD137 therapy and ADG153, a masked
anti-CD47 IgG1 antibody, and ADG138, a novel, double masked HER2xCD3 bispecific T-cell engager (TCE) for solid tumors. All three of
these candidates are designed for improved efficacy while incorporating precision masking peptides to ensure safety of such powerful
modalities," said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene. "Additionally, we are
establishing a new paradigm for CD28 TCEs by targeting a unique, highly conserved epitope for local activation, and leveraging
SAFEbody to ensure ultimate safety and mitigate known risks of this target. We are very excited to show potential differentiation of
these preclinical candidates, and spotlight our ability to create first/best-in-class product candidates that can be safely and
effectively combined together as we aspire to cure cancer."
Key takeaways from the four posters include:
ADG206, an anti-CD137 agonistic
POWERbody with tailor-made efficacy and safety profiles by strong crosslinking and tumor selective activation for single
agent and combinational cancer immunotherapy (#2868)
ADG153-G1 SAFEbody, a
differentiated masked anti-CD47 antibody of IgG1 subclass, demonstrates in vivo anti-tumor activity consistent with enhanced
ADCC/ADCP effects and significantly reduced RBC-related and antigen sink liabilities" (#4257)
ADG138, A Novel HER2 CD3
POWERbody Integrating Bispecific TCE with Precision Masking to Control Cytokine Release Syndrome and On-Target Off-Tumor Toxicity
for Single Agent and Combination Therapies in HER2-Expressing Solid Tumors (#2869)
Tumor-targeted CD28 bispecific
POWERbody for safe and synergistic
T cell-mediated immunotherapy (#2888)
Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development
of novel antibody-based cancer immunotherapies. Adagene combines computational
biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic
Precision Library (DPL) platform, composed of NEObody , SAFEbody , and POWERbody technologies, Adagene's highly
differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners
that leverage its technology in multiple approaches at the vanguard of science.
more information, please visit: https://investor.adagene.com. Follow Adagene on WeChat, LinkedIn and Twitter.
a registered trademark in the United States, China, Australia, Japan, Singapore,
and the European Union.
Safe Harbor Statement
press release contains forward-looking statements, including statements regarding the preclinical studies of ADG138, ADG206, ADG153 and
a tumor-targeted CD28 bispecific POWERbody , the potential
implications of preclinical findings of these product candidates, and Adagene's advancement of, and anticipated clinical development,
regulatory milestones and commercialization of Adagene pipeline candidates. Actual results may differ materially from those indicated
in the forward-looking statements as a result of various important factors, including but not limited to Adagene's ability to demonstrate
the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development
or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval
of Adagene's drug candidates; Adagene's ability to achieve commercial success for its drug candidates, if approved; Adagene's
ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene's reliance on third parties
to conduct drug development, manufacturing and other services; Adagene's limited operating history and Adagene's ability
to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene's
ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact
of the COVID-19 pandemic on Adagene's clinical development, commercial and other operations, as well as those risks more fully
discussed in the "Risk Factors" section in Adagene's
filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available
to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward looking statements, whether as a result of
new information, future events or otherwise, except as may be required by law.
Investor & Media Contact: